SNGX - Soligenix, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.3400
+0.0400 (+1.21%)
At close: 4:00PM EST

3.3200 -0.02 (-0.60%)
After hours: 4:00PM EST

Stock chart is not supported by your current browser
Previous Close3.3000
Open3.3500
Bid3.3300 x 1100
Ask3.3600 x 800
Day's Range3.1200 - 3.5400
52 Week Range0.6500 - 3.5400
Volume892,613
Avg. Volume358,504
Market Cap68.981M
Beta (5Y Monthly)1.16
PE Ratio (TTM)N/A
EPS (TTM)-0.5160
Earnings DateMar 23, 2020 - Mar 29, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.75
  • Newsfile

    Independent Case Study For Soligenix's CTCL Drug, SGX301, Drives Bullish Sentiment; Topline "FLASH" Trial Data Expected Q1 2020

    Miami Beach, Florida--(Newsfile Corp. - February 20, 2020) - Soligenix may be nearing a transformative point in its history as data from its Phase 3 SGX301 (FLASH) trial to treat cutaneous T-cell lymphoma (CTCL) nears its release. The topline data from this late-stage study is expected in less than 40 days. And, if that release can validate data known from a recent case study performed by Dr. Brian Poligone, MD, Ph.D., then Soligenix ...

  • Zacks Small Cap Research

    SNGX: KOL Interview with Dr. Brian Poligone, an Investigator in P3 FLASH Study in CTCL…

    By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Soligenix, Inc. (NASDAQ:SNGX) is currently conducting a Phase 3 clinical trial of SGX301 in patients with cutaneous T cell lymphoma (CTCL). The FLASH (Fluorescent Light Activated Synthetic Hypericin) trial is a randomized, double blind, placebo controlled study that was originally expected to enroll approximately 120 subjects with

  • Benzinga

    The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 12) AbbVie Inc (NYSE: ABBV ) Agile Therapeutics Inc (NASDAQ: ...

  • PR Newswire

    FDA Grants Soligenix "Fast Track" Designation for RiVax® in the Prevention of Ricin Poisoning

    Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its RiVax® (heat stable ricin toxin vaccine) development program for prevention of ricin intoxication has received "Fast Track" designation from the US Food and Drug Administration (FDA).

  • PR Newswire

    Soligenix Announces SGX301 Patient Case Study Presentation at the 4th World Congress of Cutaneous Lymphomas

    Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Dr. Brian Poligone, clinical investigator and lead enroller in the pivotal Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) study evaluating SGX301 in the treatment of early stage cutaneous T-cell lymphoma (CTCL), will present a patient case study from the trial. The presentation will be given at the upcoming 4th World Congress of Cutaneous Lymphomas on February 12-14, in Barcelona, Spain.

  • PR Newswire

    Soligenix Announces Japanese Patent Allowance for Use of Dusquetide in Oral Mucositis

    Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Japanese Patent Office has granted the patent titled "Novel Peptides and Analogs for Use in the Treatment of Oral Mucositis." This allowance builds on similar intellectual property in the United States (US), New Zealand, Australia and Singapore and patent applications pending in other jurisdictions worldwide. The new claims cover therapeutic use of dusquetide (active ingredient in SGX942) and related innate defense regulator (IDR) analogs, and add to composition of matter claims for dusquetide and related analogs that have been granted in the US and worldwide. Dusquetide previously demonstrated positive results in a Phase 2 oral mucositis clinical trial and a pivotal Phase 3 study is ongoing, with a positive interim analysis completed in August 2019 and final topline results expected in Q2 2020.

  • Newsfile

    Soligenix Stock Jumps 95% YTD Ahead of Topline Data Release For SGX301; Targeting $250 Million Unmet Market Opportunity To Treat CTCL

    Positive results, expected in Q1 2020, can position SGX301 as the first FDA-approved front-line therapy to treat Cutaneous T-cell Lymphoma (CTCL) Miami Beach, Florida--(Newsfile Corp. - January 30, 2020) - Soligenix (NASDAQ: SNGX) stock continued its price surge with gains exceeding 95% since the first of the year*. Investors are eyeing the near-term release of topline data for its late-stage drug candidate, SGX301, targeting the treatment of CTCL. If the results are consistent with ...

  • PR Newswire

    Soligenix to Present at the 22nd Annual BIO CEO & Investor Conference

    Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will deliver a corporate presentation reviewing the Company's two Phase 3 clinical programs and pipeline at the 22nd Annual BIO CEO & Investor Conference in New York City, Tuesday, February 11, 2020 at 9:45 AM EST. The presentation will take place at the New York Marriott Marquis, Wilder Room, 4th Floor.

  • Is Soligenix (NASDAQ:SNGX) In A Good Position To Deliver On Growth Plans?
    Simply Wall St.

    Is Soligenix (NASDAQ:SNGX) In A Good Position To Deliver On Growth Plans?

    Just because a business does not make any money, does not mean that the stock will go down. For example, Soligenix...

  • Newsfile

    Soligenix Shares Power Higher Ahead of SGX301 Phase 3 Data Release; Projected $200 Million Revenue Opportunity For CTCL Drug

    Soulstring Media spots a substantial value opportunity in Soligenix, Inc.; Two near-term Phase 3 data releases can seize upon a $400 million drug market opportunity Miami Beach, Florida--(Newsfile Corp. - January 16, 2020) - Soligenix (NASDAQ: SNGX), a late-stage pharmaceutical company working to improve the current standard of care for numerous rare diseases through the development and commercialization of novel treatments, is nearing the release of topline data after completing final enrollment for SGX301, a ...

  • Zacks Small Cap Research

    SNGX: Interview with Dr. Straube Regarding the Upcoming Phase 3 CTCL Data Readout…

    By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Interview with Dr. Richard Straube Regarding Upcoming Phase 3 Data for SGX301 in CTCL Soligenix, Inc. (NASDAQ:SNGX) recently announced the completion of enrollment in the Phase 3 clinical trial of SGX301 in patients with cutaneous T cell lymphoma (CTCL). The FLASH (Fluorescent Light Activated Synthetic Hypericin)

  • How Much is Soligenix, Inc.'s (NASDAQ:SNGX) CEO Getting Paid?
    Simply Wall St.

    How Much is Soligenix, Inc.'s (NASDAQ:SNGX) CEO Getting Paid?

    Christopher Schaber became the CEO of Soligenix, Inc. (NASDAQ:SNGX) in 2006. First, this article will compare CEO...

  • PR Newswire

    Soligenix to Receive $850,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program

    Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received preliminary approval for a tax credit from the New Jersey Economic Development Authority's (NJEDA) New Jersey Technology Business Tax Certificate Transfer program. As a result, the Company anticipates being able to transfer this credit and receive approximately $850,000 in net proceeds.

  • Newsfile

    CORRECTION FROM SOURCE: Major Milestones for Soligenix Bring 2019 to a Strong Close

    New York, New York--(Newsfile Corp. - December 13, 2019) - This news release has been corrected to add legal disclaimers. As the end of the year's fourth quarter comes to a close, CEO3in60 highlights how Soligenix (NASDAQ: SNGX) has achieved multiple milestones across the company's core focus areas. Two treatments in development to treat rare diseases and/or areas of unmet medical need are currently in Phase 3 studies. Additionally, the Public Health Solutions arm has ...

  • PR Newswire

    Soligenix Initiates Clinical Trial of its Heat Stable Ricin Toxin Vaccine

    Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has opened the study titled "A Phase 1C, Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Safety of RiVax®, a Lyophilized Ricin Toxin A-Chain Subunit Vaccine with Alum-Adjuvant, in Healthy, Normal Adults." Preliminary safety results from the trial are expected in the second quarter of 2020 with longer-term safety and immunogenicity results from throughout the 6-month follow-up period expected in the fourth quarter of 2020.

  • Newsfile

    Major Milestones for Soligenix Bring 2019 to a Strong Close

    New York, New York--(Newsfile Corp. - December 11, 2019) - As the end of the year's fourth quarter comes to a close, CEO3in60 highlights how Soligenix (NASDAQ: SNGX) has achieved multiple milestones across the company's core focus areas. Two treatments in development to treat rare diseases and/or areas of unmet medical need are currently in Phase 3 studies. Additionally, the Public Health Solutions arm has grown to operate under a multi-million-dollar contract with the National ...

  • SNGX: CTCL Phase 3 Trial Fully Enrolled; Data in 1Q20…
    Zacks Small Cap Research

    SNGX: CTCL Phase 3 Trial Fully Enrolled; Data in 1Q20…

    By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Phase 3 Trial of SGX301 in CTCL Fully Enrolled; Data in 1Q20 On December 3, 2019, Soligenix, Inc. (NASDAQ:SNGX) announced that enrollment has completed in the Phase 3 clinical trial of SGX301 in patients with cutaneous T cell lymphoma (CTCL). The FLASH (Fluorescent Light Activated Synthetic Hypericin) trial is a

  • PR Newswire

    Soligenix Completes Enrollment in its Pivotal Phase 3 Clinical Trial of SGX301 in the Treatment of Cutaneous T-cell Lymphoma

    Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today it has completed patient enrollment in its Phase 3 "Fluorescent Light Activated Synthetic Hypericin" (FLASH) study for SGX301 (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL). The study successfully enrolled 169 subjects, following positive interim analysis, which included a prospectively defined, unblinded assessment of the study's primary efficacy endpoint by an independent Data Monitoring Committee (DMC). With enrollment completed, top-line results are expected in the first quarter of 2020.

  • PR Newswire

    Soligenix to Present at the PCG Spotlight Series Conference

    PRINCETON, N.J., Nov. 18, 2019 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it will be presenting at the PCG Spotlight Series Conference taking place on Thursday, November 21, 2019 at the Harvard Club, 35 West 44th Street, NYC at 2:30 pm EST. Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix will be delivering the corporate presentation and reviewing upcoming milestones for the Company's two pivotal Phase 3 clinical programs.

  • If You Had Bought Soligenix (NASDAQ:SNGX) Stock Five Years Ago, You'd Be Sitting On A 94% Loss, Today
    Simply Wall St.

    If You Had Bought Soligenix (NASDAQ:SNGX) Stock Five Years Ago, You'd Be Sitting On A 94% Loss, Today

    Soligenix, Inc. (NASDAQ:SNGX) shareholders should be happy to see the share price up 12% in the last month. But will...

  • SNGX: Two Phase 3 Data Readouts Over the Next Two Quarters…
    Zacks Small Cap Research

    SNGX: Two Phase 3 Data Readouts Over the Next Two Quarters…

    By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Two Phase 3 Data Readouts in 2020 Soligenix, Inc. (NASDAQ:SNGX) is a late-stage clinical biopharmaceutical company developing treatments in oncology, GI disorders, and biodefense. The company has a number of important near-term catalysts that we believe should be on investor’s radars, including: • 1Q2020 – topline

  • PR Newswire

    Soligenix Announces Recent Accomplishments And Third Quarter 2019 Financial Results

    PRINCETON, N.J., Nov. 12, 2019 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended September 30, 2019. Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix stated, "We are now approaching data read-out in two Phase 3 clinical programs. Following the recent positive recommendation received from the independent Data Monitoring Committee (DMC), we continue to enroll patients in our pivotal double-blind, placebo-controlled Phase 3 clinical trial of SGX942 (dusquetide) for the treatment of oral mucositis in patients with head and neck cancer (HNC) receiving chemoradiation therapy.

  • PR Newswire

    Soligenix to Present at the 25th Annual BIO-Europe International Partnering Conference

    PRINCETON, N.J., Nov. 6, 2019 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Daniel P. Ring, Vice President of Business Development and Strategic Planning, will deliver a corporate presentation reviewing the Company's two Phase 3 clinical programs and pipeline at the 25th Annual BIO-Europe International Partnering Conference in Hamburg, Germany, Tuesday, November 12, 2019 at 10:45 AM GMT. The event will take place at Hamburg Messe, Level 1, Hall B1, room 7.

  • PR Newswire

    Soligenix Receives US Patent for Improved Production of Synthetic Hypericin Composition

    Active Ingredient in SGX301 for the Treatment of Cutaneous T-Cell Lymphoma PRINCETON, N.J. , Oct. 24, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical ...

  • Newsfile

    Catalyst Watch: Soligenix Inc.'s SGX301 and SGX942 Upcoming Data Release Can Change the CTCL and Oral Mucositis Treatment Landscape

    Miami Beach, Florida--(Newsfile Corp. - October 22, 2019) - There are two things that developing biotechs need for success. First, they need a good drug. Second, they need cash to fund clinical trials. Soligenix has both (NASDAQ: SNGX). Combined, the two may offer Soligenix investors a near-term opportunity to enjoy the rewards of both an FDA approval and the subsequent commercial launch of at least two promising drugs, SGX301 and SGX942, each targeting ...